2型糖尿病合并冠心病患者采用达格列净治疗的临床效果观察  

Observation on the clinical effect of dapagliflozin in patients with type 2 diabetes mellitus and coronary heart disease

作　　者：刘先仕 李萍 LIU Xian-shi;LI Ping(Gaomi People's Hospital,Gaomi 261500,China)

机构地区：[1]高密市人民医院,261500

出　　处：《中国实用医药》2024年第12期102-106,共5页China Practical Medicine

摘　　要：目的观察2型糖尿病合并冠状动脉粥样硬化性心脏病(冠心病)患者采用达格列净治疗的临床效果。方法选择2型糖尿病合并冠心病患者180例,根据随机数字表法分为参照组及研讨组,各90例。参照组患者在标准冠心病治疗基础上添加阿卡波糖治疗,研讨组患者在标准冠心病治疗基础上添加达格列净治疗。比较两组患者治疗前后的血糖指标(糖化血红蛋白、空腹血糖、餐后2 h血糖)、血脂指标(甘油三酯、血清总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇)及炎症因子(C反应蛋白、白细胞介素-6、白细胞介素-8)水平,不良心血管事件发生情况。结果治疗后,研讨组患者的糖化血红蛋白(5.02±1.29)%、空腹血糖(6.03±1.34)mmol/L、餐后2 h血糖(8.08±1.05)mmol/L低于参照组患者的(7.54±1.31)%、(7.02±1.59)mmol/L、(9.13±1.24)mmol/L,组间对比具统计学差异(P<0.05)。治疗后,研讨组患者的甘油三酯(1.36±0.27)mmol/L、血清总胆固醇(4.15±1.01)mmol/L、低密度脂蛋白胆固醇(2.26±0.39)mmol/L低于参照组的(1.94±0.43)、(5.05±1.08)、(3.21±0.78)mmol/L,高密度脂蛋白胆固醇(1.59±0.67)mmol/L高于参照组的(1.08±0.56)mmol/L,组间对比具统计学差异(P<0.05)。治疗后,研讨组患者的C反应蛋白(5.95±1.28)mg/L、白细胞介素-6(9.34±1.51)ng/L、白细胞介素-8(76.21±10.34)pg/ml低于参照组的(8.76±1.78)mg/L、(16.04±2.46)ng/L、(83.12±10.75)pg/ml,组间对比具统计学差异(P<0.05)。治疗过程中,研讨组患者的不良心血管事件发生率4.44%低于参照组患者的17.78%,组间对比具统计学差异(P<0.05)。结论2型糖尿病合并冠心病患者采用达格列净治疗的临床效果良好,能够对患者的各项临床指标有效调节,延缓病情发展,提升安全性。Objective To observe the clinical effect of dapagliflozin in patients with type 2 diabetes mellitus and coronary heart disease.Methods A total of 180 patients with type 2 diabetes mellitus and coronary heart disease were divided into a reference group and a study group according to random number table method,with 90 patients in each group.The reference group was treated with acarbose on the basis of standard coronary heart disease treatment,and the study group was treated with dapagliflozin on the basis of standard coronary heart disease treatment.Patients in both groups were compared in terms of levels of blood glucose indexes(glycosylated hemoglobin,fasting blood glucose,2 h postprandial blood glucose),blood lipid indexes(triglyceride,serum total cholesterol,low density lipoprotein cholesterol,high density lipoprotein cholesterol),inflammatory factors(C-reactive protein,interleukin-6,interleukin-8)before and after treatment,and adverse cardiovascular events.Results After treatment,the study group had glycosylated hemoglobin of(5.02±1.29)%,fasting blood glucose of(6.03±1.34)mmol/L,and 2 h postprandial blood glucose of(8.08±1.05)mmol/L,which were lower than(7.54±1.31)%,(7.02±1.59)mmol/L and(9.13±1.24)mmol/L in the reference group,and the difference between groups was statistically significant(P<0.05).After treatment,the study group had triglyceride of(1.36±0.27)mmol/L,serum total cholesterol of(4.15±1.01)mmol/L,and low density lipoprotein cholesterol of(2.26±0.39)mmol/L,which were lower than(1.94±0.43),(5.05±1.08),and(3.21±0.78)mmol/L in the reference group;the study group had higher high density lipoprotein cholesterol of(1.59±0.67)mmol/L than(1.08±0.56)mmol/L in the reference group;the difference between groups was statistically significant(P<0.05).After treatment,the study group had C-reactive protein of(5.95±1.28)mg/L,interleukin-6 of(9.34±1.51)ng/L,and interleukin-8 of(76.21±10.34)pg/ml,which were lower than(8.76±1.78)mg/L,(16.04±2.46)ng/L,and(83.12±10.75)pg/ml in the reference group,the

关 键 词：2型糖尿病 冠状动脉粥样硬化性心脏病 达格列净 临床效果 

分 类 号：R587.1[医药卫生—内分泌] R541.4[医药卫生—内科学]